EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Computational modeling of intravitreal ranibizumab kinetics: Predicting macular drug concentration and half-life

Jabia Mostofa Chowdhury iD

PLOS One · 07.05.2026 · 21 (5) · e0348811

DOI: 10.1371/journal.pone.0348811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 07.05.2026. Verfasst von Jabia Mostofa Chowdhury. Beteiligte Einrichtung: Department of Electrical Engineering, Texas A&M University-Texarkana, Texarkana, Texas, United States of America. Hauptthemen laut MEDLINE: Ranibizumab, Computer Simulation, Models, Biological, Macula Lutea. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ranibizumab is a key anti-VEGF therapeutic used to improve treatment efficacy and reduce injection frequency in neovascular retinal diseases. Because experimental pharmacokinetic data in humans are limited, computational modeling provides an effective means to predict ocular drug behavior. In this study, a three-dimensional computational model of the human eye was developed in COMSOL Multiphysics 6.3 to analyze the pharmacokinetics of ranibizumab following intravitreal injection. The model also quantified drug concentration near the macula, the primary target site for neovascular disease, and evaluated it against the minimum threshold concentration required for VEGF suppression. Fluid flow in the vitreous was represented by Darcy’s law, while drug convection and diffusion were modeled using the transport of diluted species equation. Four physiological scenarios combining vitreous state (normal vs. partially liquefied) and elimination pathways (anterior dominant vs. both routes) were simulated. Predicted intravitreal half-lives ranged from 2.7 to 4.4 days, consistent with reported human data (2.4 ~ 9 days). The model demonstrates a plausible representation of physiologically relevant ocular pharmacokinetics and provides a computational framework that may assist in exploring dosing strategies and informing the design of intravitreal drug delivery systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RanibizumabComputer SimulationModels, BiologicalMacula LuteaAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedHumansIntravitreal InjectionsHalf-LifeVitreous BodyVascular Endothelial Growth Factor AKinetics

Substanzen

RanibizumabAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Electrical Engineering, Texas A&M University-Texarkana, Texarkana, Texas, United States of America.

ORCID-Profile: Jabia Mostofa Chowdhury

Zitieren

APA

Chowdhury, J. M. (2026). Computational modeling of intravitreal ranibizumab kinetics: Predicting macular drug concentration and half-life. PLOS One, 21(5), e0348811. https://doi.org/10.1371/journal.pone.0348811

Vancouver

Chowdhury JM. Computational modeling of intravitreal ranibizumab kinetics: Predicting macular drug concentration and half-life. PLOS One. 2026;21(5):e0348811. doi:10.1371/journal.pone.0348811

BibTeX
@article{Chowdhury2026,
  author = {Chowdhury, Jabia Mostofa},
  title = {Computational modeling of intravitreal ranibizumab kinetics: Predicting macular drug concentration and half-life},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {5},
  pages = {e0348811},
  doi = {10.1371/journal.pone.0348811}
}
Kostenlos starten →